What is your preferred first line regimen for a patient with BRCA+ metastatic pancreatic cancer with poor performance status?  

The key question here is, "Are there any data to support the use of maintenance olaparib in BRCA-mutated patients after non-cisplatin first line chemotherapy?" This question arises from the results of the POLO trial which showed improvement in progression-free survival with the use of maintenance ol...

One could consider, in this situation, offering initially attenuated doses of gemzar/abraxane and cisplatin and gradually increasing as tolerated. Gemzar and abraxane were initially approved in patients including PS 2 as opposed to folfirinox which only included patients with PS 0-1. In my experienc...